A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer-Reference-Cited by-同舟云学术

A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer

Published:2017-05 Issue: Volume:89 Page:875-879
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Wang Ying,Wang Hui,Jiang Yiling,Zhang Yaping,Wang Xiaoyan

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference26 articles.

1. Epidemiology, prevention and risk morbidity factors for lung cancer;Radziszewska;Pol. Merkur. Lekarski,2015

2. Annual report on status of cancer in China, 2011;Chen;Chin. J. Cancer Res.,2015

3. National cancer incidence and mortality in China, 2012;Chen;Chin. J. Cancer Res.,2016

4. Cancer statistics, 2016;Siegel;CA. Cancer J. Clin.,2016

5. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women;Malvezzi;Ann. Oncol.,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

2. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01

3. Antitumor effects of erlotinib in combination with berberine in A431 cells;BMC Pharmacology and Toxicology;2023-05-11

4. Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks;International Journal of Molecular Sciences;2023-01-23

5. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials;BMJ Open;2022-08